Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 6/20 | 0.54 |
| ▸ | DRD2 | P14416 | 5/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | C1S | P09871 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4607941 | 0.83 | GRIN2B (0.47) | GRIN2BGRIN2AKCNH2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7322276 | 0.80 | KCNH2 (0.56) | DRD3DRD2GRIN2BGRIN2AKCNH2 | |
| Hydrochloric Acid SCHEMBL7322849 | 0.80 | KCNH2 (0.56) | DRD2GRIN2BGRIN2AKCNH2 | |
| Hydrochloric Acid SCHEMBL7322321 | 0.78 | KCNH2 (0.58) | DRD2GRIN2BGRIN2AKCNH2DRD4 | |
| SCHEMBL3187453 | 0.75 | DRD3 (0.74) | DRD3DRD2KCNH2DRD4 | |
| Hydrochloric Acid SCHEMBL7324295 | 0.74 | GRIN2B (0.63) | DRD2GRIN2BGRIN2AKCNH2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3207069 | 0.74 | DRD3 (0.72) | DRD3DRD2KCNH2DRD4 | |
| SCHEMBL4608739 | 0.74 | GRIN2B (0.52) | DRD3DRD2GRIN2BGRIN2AKCNH2 | |
| Hydrochloric Acid SCHEMBL7323720 | 0.73 | HTR1A (0.53) | GRIN2BALDH1A1 | |
| Hydrochloric Acid SCHEMBL7322789 | 0.72 | GRIN2B (0.53) | DRD2GRIN2BGRIN2ADRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785447-B2 | Use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-22 | — | — | US | claimed |
| EP-1272187-B1 | DOPAMINE-D3 RECEPTOR LIGANDS FOR THE TREATMENT OF ADDICTION | ABBOTT GMBH & CO KG (DE) | 2008-07-30 | — | — | EP | claimed |
| US-20060223793-A1 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-10-05 | — | — | US | claimed |
| US-7098214-B1 | Dopamine D3 receptor ligands or antagonists for use in the treatment of renal function disorders | ABBOTT GMBH & CO. KG (DE) | 2006-08-29 | — | — | US | claimed |
| US-8785447-B2 | Use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-22 | — | — | US | disclosed |
| EP-1272187-B1 | DOPAMINE-D3 RECEPTOR LIGANDS FOR THE TREATMENT OF ADDICTION | ABBOTT GMBH & CO KG (DE) | 2008-07-30 | — | — | EP | disclosed |
| US-20060223793-A1 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-10-05 | — | — | US | disclosed |
| US-7098214-B1 | Dopamine D3 receptor ligands or antagonists for use in the treatment of renal function disorders | ABBOTT GMBH & CO. KG (DE) | 2006-08-29 | — | — | US | disclosed |
| EP-1176963-B1 | USE OF DOPAMINE D 3 RECEPTOR ANTAGONISTS FOR PRODUCING MEDICAMENTS FOR TREATING KIDNEY DISORDERS | ABBOTT GMBH & CO KG (DE) | 2004-12-15 | — | — | EP | disclosed |
| US-20030087917-A1 | Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087917-A1 | Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system | DRD3, DRD2, OPRD1 | DRD3 1/4885DRD2 2/4885GRIN2B 30/4885 |
| US-20060223793-A1 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS | SLC6A3, DRD3, DRD2 | DRD3 2/4885DRD2 3/4885GRIN2B 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.